Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
Status:
RECRUITING
Trial end date:
2027-08-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and side effects of Zanubrutinib combined with Obinutuzumab (ZO) in the treatment of newly diagnosed follicular lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Collaborators:
Fujian Cancer Hospital Huazhong University of Science and Technology Jiangxi Provincial Cancer Hospital Shaanxi Provincial Cancer Hospital Sun Yat-sen University The First Hospital of Jilin University The Second Affiliated Hospital of Dalian Medical University